AVADEL PHARMACEUTICALS PLC 4

CFO Thomas S. McHugh had 100,400 Avadel ordinary shares and options over 1,004,500 shares cashed out or canceled for cash and contingent value rights at $21.00 per share in connection with the Alkermes acquisition.

On February 12, 2026, Thomas S. McHugh, Chief Financial Officer of Avadel Pharmaceuticals plc, reported the automatic disposition of 100,400 ordinary shares at $21.00 per share in cash plus contingent value rights in connection with the closing of Avadel’s acquisition by Alkermes plc under an Irish scheme of arrangement. On the same date, all of his outstanding stock options covering an aggregate 1,004,500 ordinary shares with exercise prices ranging from $3.45 to $13.57 were canceled and converted into cash payments equal to the in-the-money value based on the $21.00 cash consideration per share plus one contingent value right for each underlying share, regardless of vesting status. Restricted stock awards vested in full at closing and were treated the same way as other ordinary shares. Following these merger-related transactions, McHugh reported zero direct ownership of Avadel ordinary shares or options, as the issuer became a wholly owned subsidiary of Alkermes and the equity was fully cashed out.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014445

Alert Tier

6